New treatments for acute myeloid leukemia using prolidase inhibitors
Prolidase Inhibitors as Therapeutic Agents for Acute Myeloid Leukemia
This study is looking at new ways to treat acute myeloid leukemia (AML) by using special agents that can help kill cancer cells while keeping inflammation low, with the hope of finding better treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11012860 on NIH RePORTER |
What this research studies
This research focuses on developing new therapeutic agents for acute myeloid leukemia (AML), a common and aggressive form of leukemia in adults. The approach involves using inhibitors of the enzyme prolidase to selectively activate the CARD8 inflammasome, which can induce cell death in AML cancer cells without causing harmful inflammation. By optimizing these inhibitors, the research aims to create effective treatments that improve patient outcomes. The study will explore the mechanisms of action and efficacy of these agents in laboratory settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with acute myeloid leukemia who have limited treatment options.
Not a fit: Patients with other types of leukemia or those who are not adults may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatment options for patients with acute myeloid leukemia.
How similar studies have performed: Other research has shown promise in using inflammasome activation for cancer treatment, suggesting that this approach could be a viable new strategy.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Bachovchin, Daniel — Sloan-Kettering Inst Can Research
- Study coordinator: Bachovchin, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.